| Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants D Wilkins, Y Yuan, Y Chang, AA Aksyuk, BS Núñez, U Wählby-Hamrén, ... Nature Medicine 29 (5), 1172-1179, 2023 | 36 | 2023 |
| Neutralizing Staphylococcus aureus virulence with AZD6389, a three mAb combination, accelerates closure of a diabetic polymicrobial wound C Tkaczyk, O Jones-Nelson, YY Shi, DE Tabor, L Cheng, T Zhang, ... Msphere 7 (3), e00130-22, 2022 | 17 | 2022 |
| Multiomics links global surfactant dysregulation with airflow obstruction and emphysema in COPD VA Hristova, A Watson, R Chaerkady, MS Glover, J Ackland, B Angerman, ... ERJ Open Research 9 (3), 2023 | 7 | 2023 |
| Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection T Brady, C Cayatte, TL Roe, SD Speer, H Ji, LA Machiesky, T Zhang, ... Frontiers in Immunology 14, 1283120, 2023 | 6 | 2023 |
| Molecular characterization of AZD7442 (tixagevimab-cilgavimab) neutralization of SARS-CoV-2 Omicron subvariants TL Roe, T Brady, N Schuko, A Nguyen, J Beloor, JD Guest, AA Aksyuk, ... Microbiology Spectrum 11 (2), e00333-23, 2023 | 6 | 2023 |
| Novel non-terminal tumor sampling procedure using fine needle aspiration supports immuno-oncology biomarker discovery in preclinical mouse models SI Sitnikova, S Munnings-Tomes, E Galvani, S Kentner, K Mulgrew, ... Journal for Immunotherapy of Cancer 9 (6), 2021 | 5 | 2021 |
| Breakthrough SARS-CoV-2 infections in the PROVENT prevention trial were not associated with AZD7442 (tixagevimab/cilgavimab) resistant variants KM Tuffy, B Ahani, AA Aksyuk, M Avila, T Brady, GH Kijak, G Koh, ... The Journal of Infectious Diseases 228 (8), 1055-1059, 2023 | 3 | 2023 |
| Mean comparisons and power calculations to ensure reproducibility in preclinical drug discovery S Novick, T Zhang Statistics in Medicine 40 (6), 1414-1428, 2021 | 3 | 2021 |
| Qualification of a Biolayer Interferometry Assay to support AZD7442 resistance monitoring T Brady, T Zhang, KM Tuffy, N Haskins, Q Du, J Lin, G Kaplan, S Novick, ... Microbiology Spectrum 10 (5), e01034-22, 2022 | 2 | 2022 |
| Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial) GH Kijak, B Ahani, D Arbetter, F Chuecos, V Gopalakrishnan, J Beloor, ... Infectious Diseases and Therapy 12 (12), 2691-2707, 2023 | 1 | 2023 |
| A comparison of statistical methods for animal oncology studies T Zhang, SJ Novick Pharmaceutical Statistics 22 (1), 112-127, 2023 | 1 | 2023 |
| Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants (vol 29, pg 1172, 2023) D Wilkins, Y Yuan, Y Chang, AA Aksyuk, BS Nunez, U Waehlby-Hamren, ... NATURE MEDICINE, 2024 | | 2024 |
| Author Correction: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants D Wilkins, Y Yuan, Y Chang, AA Aksyuk, BS Núñez, U Wählby-Hamrén, ... Nature medicine, 2024 | | 2024 |
| Whole-cage randomization for animal studies with unequal cage or group sizes T Zhang, B Phillips, N Karp, J Wang, S Novick Journal of Biopharmaceutical Statistics, 1-11, 2023 | | 2023 |
| 1110. AZD7442 (Tixagevimab/Cilgavimab) Demonstrates Potent In Vitro Activity Against SARS-CoV-2 Spike Variants Identified in Circulation and in Prophylaxis Clinical Studies KM Tuffy, ME Abram, TL Roe, B Ahani, T Brady, N Schuko, L Clarke, ... Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 949, 2022 | | 2022 |
| AZD7442 (Tixagevimab/Cilgavimab) Demonstrates Potent In Vitro Activity Against SARS-CoV-2 Spike Variants Identified in Circulation and in Prophylaxis Clinical Studies KM Tuffy, ME Abram, TL Roe, B Ahani, T Brady, N Schuko, L Clarke, ... Open Forum Infectious Diseases, S473-S473, 2022 | | 2022 |
| A novel non-terminal tumor sampling procedure using fine needle aspiration supports biomarker discovery SI Sitnikova, S Munnings-Tomes, SR Kentner, K Mulgrew, ... Cancer Research 81 (13_Supplement), 2768-2768, 2021 | | 2021 |
| Dysregulation of COVID-19 related gene expression in the COPD lung. B Angerman, S Ashenden, S Bawden, G Belfield, MG Belvisi, A Bornot, ... Respiratory Research 22 (1), NA-NA, 2021 | | 2021 |
